GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (LTS:0NZU) » Definitions » Cyclically Adjusted Price-to-FCF

Zealand Pharma A/S (LTS:0NZU) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Zealand Pharma A/S Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Zealand Pharma A/S's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Cyclically Adjusted Price-to-FCF Chart

Zealand Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zealand Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zealand Pharma A/S's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Zealand Pharma A/S's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Cyclically Adjusted Price-to-FCF falls into.



Zealand Pharma A/S Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Zealand Pharma A/S's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Zealand Pharma A/S's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-3.687/118.4000*118.4000
=-3.687

Current CPI (Mar. 2024) = 118.4000.

Zealand Pharma A/S Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -2.298 99.700 -2.729
201409 0.195 99.700 0.232
201412 -1.665 99.400 -1.983
201503 -2.713 100.200 -3.206
201506 -2.525 100.300 -2.981
201509 -2.700 100.200 -3.190
201512 -1.973 99.800 -2.341
201603 1.732 100.200 2.047
201606 -2.693 100.600 -3.169
201609 -1.933 100.200 -2.284
201612 4.224 100.300 4.986
201703 -2.053 101.200 -2.402
201706 -4.820 101.200 -5.639
201709 0.013 101.800 0.015
201712 -3.411 101.300 -3.987
201803 -3.043 101.700 -3.543
201806 -3.734 102.300 -4.322
201809 -3.459 102.400 -3.999
201812 -4.926 102.100 -5.712
201903 1.575 102.900 1.812
201906 -4.415 102.900 -5.080
201909 -5.007 102.900 -5.761
201912 -4.850 102.900 -5.581
202003 -5.983 103.300 -6.858
202006 -3.010 103.200 -3.453
202009 -2.853 103.500 -3.264
202012 -6.721 103.400 -7.696
202103 -8.840 104.300 -10.035
202106 -7.568 105.000 -8.534
202109 -4.879 105.800 -5.460
202112 -7.502 106.600 -8.332
202203 -7.427 109.900 -8.001
202206 -5.151 113.600 -5.369
202209 -2.734 116.400 -2.781
202212 -5.467 115.900 -5.585
202303 -3.841 117.300 -3.877
202306 -3.071 116.400 -3.124
202309 -2.030 117.400 -2.047
202312 0.842 116.700 0.854
202403 -3.687 118.400 -3.687

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zealand Pharma A/S  (LTS:0NZU) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Zealand Pharma A/S Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (LTS:0NZU) Business Description

Industry
Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma A/S (LTS:0NZU) Headlines

No Headlines